MD1003 100mg capsule ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02936037 (ClinicalTrials.gov)	December 2016	14/10/2016	Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)	Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule;Drug: PLACEBO	MedDay Pharmaceuticals SA	NULL	Terminated	18 Years	65 Years	All	642	Phase 3	United States;Australia;Belgium;Canada;Czechia;Germany;Hungary;Italy;Poland;Spain;Sweden;Turkey;United Kingdom;Czech Republic;Netherlands
2	NCT02220244 (ClinicalTrials.gov)	October 2013	18/8/2014	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule	MedDay Pharmaceuticals SA	NULL	Active, not recruiting	18 Years	75 Years	All	105	Phase 3	France;United Kingdom
3	NCT02220933 (ClinicalTrials.gov)	October 2013	18/8/2014	Effect of MD1003 in Spinal Progressive Multiple Sclerosis	Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule;Drug: Placebo	MedDay Pharmaceuticals SA	NULL	Active, not recruiting	18 Years	75 Years	All	144	Phase 3	France